Literature DB >> 14527677

Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle.

K E Wells1, S Fletcher, C J Mann, S D Wilton, D J Wells.   

Abstract

The use of antisense oligonucleotides (AOs) to induce exon skipping leading to generation of an in-frame dystrophin protein product could be of benefit in around 70% of Duchenne muscular dystrophy patients. We describe the use of hyaluronidase enhanced electrotransfer to deliver uncomplexed 2'-O-methyl modified phosphorothioate AO to adult dystrophic mouse muscle, resulting in dystrophin expression in 20-30% of fibres in tibialis anterior muscle after a single injection. Although expression was transient, many of the corrected fibres initially showed levels of dystrophin expression well above the 20% of endogenous previously shown to be necessary for phenotypic correction of the dystrophic phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527677     DOI: 10.1016/s0014-5793(03)00904-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

Review 2.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

3.  Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Authors:  Camilla Brolin; Takehiko Shiraishi
Journal:  Artif DNA PNA XNA       Date:  2011-01

Review 4.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

5.  Polymersome delivery of siRNA and antisense oligonucleotides.

Authors:  Younghoon Kim; Manorama Tewari; J David Pajerowski; Shenshen Cai; Shamik Sen; Jason H Williams; Jason Williams; Shashank R Sirsi; Shashank Sirsi; Gordon J Lutz; Gordon Lutz; Dennis E Discher
Journal:  J Control Release       Date:  2008-11-12       Impact factor: 9.776

Review 6.  Progress in muscular dystrophy research with special emphasis on gene therapy.

Authors:  Hideo Sugita; Shin'ichi Takeda
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

7.  Gene therapy for muscular dystrophies: progress and challenges.

Authors:  Kyung Seok Park; Donghoon Oh
Journal:  J Clin Neurol       Date:  2010-10-01       Impact factor: 3.077

8.  Formulation of polylactide-co-glycolic acid nanospheres for encapsulation and sustained release of poly(ethylene imine)-poly(ethylene glycol) copolymers complexed to oligonucleotides.

Authors:  Shashank R Sirsi; Rebecca C Schray; Margaret A Wheatley; Gordon J Lutz
Journal:  J Nanobiotechnology       Date:  2009-04-07       Impact factor: 10.435

9.  Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice.

Authors:  Jason H Williams; Rebecca C Schray; Shashank R Sirsi; Gordon J Lutz
Journal:  BMC Biotechnol       Date:  2008-04-02       Impact factor: 2.563

10.  Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy.

Authors:  John Cw Hildyard; Dominic J Wells
Journal:  PLoS Curr       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.